Study Complete
Sponsor ID
20020112
Pegfilgrastim PBPC Mobilization Study
Study Details
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.
Protocol Summary
Primary Outcome Measures
CD34+ collection during the collection phase
Timeframe: 10 days
Secondary Outcome Measures
Time to ANC and platelet engraftment post-transplant
Timeframe: 100 days
Locations
No locations found.